Corporate presentation delivered by President and CEO, Alison Silva at the 2017 Cantech Investment Conference in Toronto on January 18th.

1. Advancing the Treatment of Cancer
Through Targeted Therapeutics
January 2017

2. 2
When used anywhere in this presentation, whether oral or written, the words expects,
believes, anticipates, estimates and similar expressions are intended to identify forward-
looking statements. Forward-looking statements may include statements addressing
future financial and operating results of Critical Outcome Technologies Inc. (COTI).
COTI bases these forward-looking statements on its current expectations about future
events. Such statements are subject to risks and uncertainties including, but not limited
to, the successful implementation of COTI’s strategic plans, the acceptance of new
products, the obsolescence of existing products, the resolution of potential patent
issues, competition, changes in economic conditions, and other risks described in COTI’s
public documents such as press releases and filings with the Toronto Stock Exchange and
the Ontario Securities Commission.
All forward-looking statements are qualified in their entirety by the cautionary
statements included in this document and such filings. These risks and uncertainties
could cause actual results to differ materially from results expressed or implied by
forward-looking statements contained in this presentation. These forward-looking
statements speak only as of the date of this presentation.
Disclaimer

3. 3
• Clinical stage biotech company focused
on the development of novel
therapeutics for the treatment of
cancers and other unmet medical needs
• Pipeline of internally developed
compounds
• CHEMSAS platform – in silico high
throughput screening for molecule
identification
• ROSALIND technology – genomics
profiling for personalized oncology care
• Offices in London, ON and Boston, MA
TSX-V: COT
OTCQB: COTQF
Company and Pipeline Synopsis

4. • In response to cellular stress, wild-type p53 induces cell cycle arrest and/or
apoptotic cell death
• Mutant p53 promotes tumor formation (loss of tumor suppressor function)
– Mutant p53: single most important cancer-causing gene mutation known
– >50% of all human cancers
– Most frequently mutated gene in human cancer with frequencies ranging from
38% to 96%
• COTI-2 induces a wild-type-like conformational change in the p53 mutant
protein that restores sequence-specific p53 transcription
– Oral small molecule
– Low preclinical toxicity
– Active as a mono or combination therapy
– Currently in a Phase I trial in gynecological malignancies
4
COTI-2 Mechanism of Action & Synopsis
mutp53
mutp53
Sequence-specific
transactivation defective
Conformational change to a
wild-type configuration
Restoration of sequence-specific
transcriptional activity
Apoptosis,
growth arrest,
senescence
mutp53
Drug Drug

5. 5
0
50
100
150
200
0 5 9 16 23 30 37 44 51 61
TumorVolume(mm3)
Study Day
Effect of IV Treatment on OVCAR-3 Tumor Volume
Group 1 = Vehicle IV
Group 2 = COTI-2 20mg/kg IV
Group 3 = COTI-2 40mg/kg IV
0
50
100
150
200
250
0 5 9 16 23 30 37 44 51 61
TumorVolume(mm3)
Study Day
Effect of PO Treatment on OVCAR-3 Tumor Volume
Group 4 = Vehicle PO
Group 5 = COTI-2 75mg/kg PO
Group 6 = COTI-2 100mg/kg PO
* *
* * * *
* *
* * * * * * * * *
*
* * * *
*
*
* * * * * * * *
James Koropatnick, LRCC, London, ON.
Significant Tumor Growth Inhibition as a Single Agent
• COTI-2 administered IV and PO produced a significant tumor growth inhibition
as a single agent in an OVCAR-3 ovarian cancer xenograft model

6. 6
• COTI-2 as a single agent and in combination with cisplatin produced significant
tumor growth inhibition relative to untreated controls in the PCI13 pG245D head
and neck cancer xenograft models
• Cisplatin treatment alone did not yield significant tumor growth inhibition
* * * * *
* * * * *
* * *
Jeffrey Myers, U of Texas, MDACC, Houston, TX.
Significant Tumor Growth Inhibition in Combination
with Cisplatin

7. 7
Protocol
Title
A PHASE 1 STUDY OF COTI-2 FOR THE TREATMENT OF ADVANCED OR RECURRENT GYNECOLOGIC MALIGNANCIES
Study Sites MD Anderson Cancer Center, Houston, TX Northwestern University Memorial Hospital, Chicago, IL
Principal
Investigators
Dr. Shannon Westin Dr. Wilberto Neives-Niera
Study Phase Phase 1
Objective Primary
• To evaluate the safety and tolerability of COTI-2 in patients with advanced or recurrent gynecologic malignancies.
• To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of COTI-2 for the
treatment of patients with advanced or recurrent gynecologic malignancies.
Secondary
• To evaluate the pharmacokinetics of COTI-2 at all dose levels in patients with advanced or recurrent gynecologic
malignancies.
• To estimate the clinical activity of COTI-2 at all dose levels and the RP2D in patients with advanced or recurrent
gynecologic malignancies by response rate (Response Evaluation Criteria In Solid Tumors [RECIST] v1.1 criteria) and
the progression-free survival (PFS) rate at 6 months.
• To estimate the response duration for COTI-2 at all dose levels and the RP2D in patients with advanced or recurrent
gynecologic malignancies.
Exploratory
• To determine if baseline molecular aberrations, including p53 mutation, correlate with activity of COTI-2 in advanced
or recurrent gynecologic malignancies.
• To evaluate pharmacodynamic markers of COTI-2 activity at all dose levels and at the RP2D in patients with advanced
or recurrent gynecologic malignancies.
Patient
Population
• Females with ovarian, fallopian tube, primary peritoneal, endometrial or cervical cancer that is recurrent, metastatic,
or unresectable and for which no effective or curative measures exist
Sample Size • Maximum 46 patients • Dose Escalation Phase: up to 36
patients (up to 6 cohorts)
• Dose Expansion Phase: 10 patients
with ovarian cancer (one cohort)
COTI2-101 Study Summary

8. • Regular updates will be provided as each cohort commences dosing, with
Cohort 4 announced in January 2017
– Announcement of dose escalation is the only “releasable” information during
this clinical phase
• June 2017 – preliminary results on the safety and clinical activity of COTI-2
• Other trials planned in 2017 – additional multi center clinical trial programs:
– Recurrent Head and Neck Squamous Cell cancer (HNSCC)
– Soft tissue sarcoma (STS)
– Combination trials with other chemo/radiotherapies
• Final trial results and conclusions
– Mid 2017 - gynecological phase
– Late 2017 - expansion phase
8
Anticipated COTI2-101 Clinical Trial News Flow

9. • Novel and specific p53-dependent mechanism of action
• Orally bio-available and effective at low dose
• Low toxicity in preclinical development
• Opportunity for single agent and combination therapy
• No drug resistance observed
• Sensitization to radiation therapy
• Strong IP protection in place
- 8 U.S. patents issued
- 1 Japanese, 1 Canadian and 1 EU patent issued
- Additional patents pending
9
COTI-2 Best-in-Class Potential

10. 10
CORPORATE
 Appointed experienced Scientific Advisory Board
(SAB)
 Opened US office (Boston, MA) in Aug 2016
 Designated next preclinical candidate for clinical
development
COTI-2
 Granted FDA orphan drug status for ovarian cancer
 Received IND granting
 Filed for FDA orphan drug status for Li-Fraumeni
syndrome
 Published first scientific article in Oncotargets
 Commenced patient dosing of Phase 1 clinical trial
at MDACC
 Activated second clinical trial site at NWU
 Initiated fourth patient cohort of Phase 1 clinical
trial
COMPLETED UPCOMING
CORPORATE
• Strengthen the balancesheet to execute on
corporate strategies
• Establish collaborations/partnershipsfor
COTI-2, pipelineprograms and other
technologies
COTI-2
• Broaden the potential for COTI-2 in
multiple additional clinical indications and
combination therapies
• Obtain additional orphan drug
designations
COTI-219
• Continue IND-enabling studies
• File an IND by the end of 2017
Corporate Objectives

11. 11
Management Team Directors
Alison Silva, MSc
• President & CEO
• Co-founder, former EVP & COO, Synlogic
• Co-founder & Principal, The Orphan Group
Wayne Danter, MD, FRCPC
• Co-founder & CSO
• Former Associate Professor of Medicine at
Western University
Gene Kelly
• Chief Financial Officer
• Former VP Finance, Cuddy Farms
Debi Sanderson, MBA
• Director, Resourcing and Operations
Kowthar Salim, PhD, MBA
• Program Director and Senior Scientist
John Drake, LLB, Chairman
• Chairman, Whippoorwill Holdings Limited
Alison Silva, MSc, President & CEO
Wayne Danter, MD, FRCPC, Co-founder & CSO
Douglas Alexander, CPA, CA
• Chairman, Hydrogenics Corporation
Bruno Maruzzo, MASc, MBA
• President, TechnoVenture Inc.
Dave Sanderson, LLB
• President & CEO, KFL Investment
Management Inc.
John Yoo, MD FRCPC
• Professor, Chairman and City-wide Chief of
Otolaryngology – Head and Neck Surgery at
Western University
Bharatt Chowrira, PhD, JD
• President, Synlogic
Committed Leadership

12. 12
Key Company Facts
Trading
TSX Venture (2) COT
Recent Closing Price (3) $0.475
52 Week Range (3) $0.21 - 0.90
Market Capitalization (3) $70,850,257
Capital
Cash (4) $3.56 M
Basic Shares Outstanding (3) 149,158,435
Options Outstanding (3) 11,197,435
Warrants Outstanding (3) 22,163,113
Fully Diluted Shares Outstanding (3) 182,518,983
Board & management control (3) (5) 16.3%
(1) All $ amounts in CAD
(2) COTI also trades on the OTCQB as COTQF but amounts
are for the TSXV only
(3) As of the close of business Dec 31, 2016
(4) As at Dec 31, 2016 consisting of cash, cash equivalents and investments
(5) On a fully diluted basis

13. Contact:
Alison Silva
President & CEO
Office: (519) 858-5157
Mobile: (860) 798-0816
asilva@criticaloutcome.com
www.criticaloutcome.com
www.criticaloutcomeblog.com
www.facebook.com/criticaloutcome
twitter.com/criticaloutcome
www.slideshare.net/criticaloutcome